Human Tumor Cloning Assay in Breast Cancer
Author Information
Author(s): Ch. Dittrich, R. Jakesz, F. Wrba, L. Havelec, O. Haas, J. Spona, H. Holzner, R. Kolb, K. Moser
Primary Institution: University of Vienna
Hypothesis
Can the human tumor cloning assay (HTCA) provide reliable information on the prognosis and response to therapy in breast cancer patients?
Conclusion
The study found that while the HTCA can predict chemosensitivity in some cases, it did not correlate with established prognostic factors or patient survival.
Supporting Evidence
- 56% of samples were adequate for evaluation.
- Clonal growth was observed in 35% of adequate specimens.
- Effusions yielded significantly better growth than solid specimens.
- No correlation was found between clonal growth and established prognostic factors.
Takeaway
Researchers tested breast cancer samples to see how well they grow in a lab, hoping to predict how patients would respond to treatment, but the results were mixed.
Methodology
The study involved cultivating breast cancer specimens using a tumor cloning system and evaluating their growth and response to various drugs.
Limitations
The study had a low overall number of results and did not establish a clear correlation between in vitro growth and patient survival.
Participant Demographics
The study included 87 specimens from 74 different patients, with a mix of biopsies and effusions.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website